SOHO Italy 2022 | Transplantation outcomes in patients with secondary AML
Arnon Nagler, MD, Chaim Sheba Medical Center, Tel Aviv, Israel, discusses the outcomes of patients with secondary acute myeloid leukemia (sAML) undergoing stem cell transplantation. Prof. Nagler first explains the higher relapse rates and worse overall survival (OS) observed in patients with sAML versus de novo AML, and further comments on novel agents being investigated to improve these outcomes, including CPX-351. To conclude, Prof. Nagler highlights a study which compared various myeloablative conditioning regimens in sAML, and the importance of conducting more research in this space. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
